KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: Practical application of patient selection

Journal of Clinical Oncology

Volumn 27, Issue 7, 2009, Pages 1130-1136

  Jimeno, Antonio ^a   Messersmith, Wells A ^a   Hirsch, Fred R ^a   Franklin, Wilbur A ^a   Gail Eckhardt, S ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GUANINE NUCLEOTIDE BINDING PROTEIN; IRINOTECAN; KRAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OXALIPLATIN; PANITUMUMAB; PLACEBO; UNCLASSIFIED DRUG;

ACCURACY; ADD ON THERAPY; ASSAY; CANCER CHEMOTHERAPY; CANCER TISSUE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG SENSITIVITY; FEASIBILITY STUDY; GENE MUTATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; PATIENT SELECTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 61449154484     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.8168     Document Type: Review

References (52)

1. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
2. Chung KY, Shia J, Kemeny NE, et al: Cetux- imab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803-1810, 2005
3. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643-2648, 2007
4. De Roock W, Piessevaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508-515, 2008
5. Finocchiaro G, Capuzzo F, Janne K, et al: EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. J Clin Oncol 25:168s, 2007 (suppl; abstr 4021)
6. Di Fiore F, Blanchard F, Charbonnier F, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96:1166-1169, 2007
7. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007
8. Lievre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379, 2008
9. Van Cutsem E, Lanf I, D'haens G, et al: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26:5s, 2008 (suppl; abstr 2)
10. Bokemeyer C, Bondarenko I, Hartmann JT, et al: KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 26:178s, 2008 (suppl; abstr 4000)
11. Tejpar S, Peeters M, Humblet Y, et al: Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data). J Clin Oncol 26:178s, 2008 (suppl; abstr 4001)
12. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
13. Malumbres M, Barbacid M: RAS oncogenes: The first 30 years. Nat Rev Cancer 3:459-465, 2003
14. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 85:692-696, 2001
15. Esteller M, Gonzalez S, Risques RA, et al: K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 19:299-304, 2001
16. Ince WL, Jubb AM, Holden SN, et al: Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97:981-989, 2005
17. National Cancer Institute of Canada Clinical Trials and the Australasian Gastro-Intestinal Trials Group: The influence of K-Ras exon 2 mutations on outcomes in a randomized phase III trial of cetux-imab + best supportive care (BSC) versus BSC alone on patients with EGFR-positive colorectal cancer. 10th World Congress on Gastrointestinal Cancer, Barcelona, Spain, June 25-28, 2008
18. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909, 2005
19. Kelly K, Chansky K, Gaspar LE, et al: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26:2450-2456, 2008
20. O'Reilly KE, Rojo F, She QB, et al: MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:15001508, 2006
21. Jimeno A, Kulesza P, Wheelhouse J, et al: Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 96:952-959, 2007
22. Sjoblom T, Jones S, Wood LD, et al: The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274, 2006
23. Cappuzzo F, Finocchiaro G, Rossi E, et al: EGFR FISH assay predicts for response to cetux- imab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19:717-723, 2008
24. Personeni N, Fieuws S, Piessevaux H, et al: Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: A fluorescent in situ hybridization study. Clin Cancer Res 14:5869-5876, 2008
25. Rao S, Cunningham D, de Gramont A, et al: Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 22:3950-3957, 2004
26. Rinehart J, Adjei AA, Lorusso PM, et al: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456-4462, 2004
27. Adjei AA, Cohen RB, Franklin W, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139-2146, 2008
28. Frayling IM: Methods of molecular analysis: Mutation detection in solid tumours. Mol Pathol 55:73-79, 2002
29. Gallegos Ruiz MI, Floor K, Rijmen F, et al: EGFR and K-ras mutation analysis in non-small cell lung cancer: Comparison of paraffin embedded versus frozen specimens. Cell Oncol 29:257-264, 2007
30. Srinivasan M, Sedmak D, Jewell S: Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 161:1961-1971, 2002
31. Williams C, Ponten F, Moberg C, et al: A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 155: 1467-1471, 1999
32. Nollau P, Wagener C: Methods for detection of point mutations: Performance and quality assessment: IFCC Scientific Division, Committee on Molecular Biology Techniques. Clin Chem 43:1114-1128, 1997
33. Haliassos A, Chomel JC, Grandjouan S, et al: Detection of minority point mutations by modified PCR technique: A new approach for a sensitive diagnosis of tumor-progression markers. Nucleic Acids Res 17:8093-8099, 1989
34. Levi S, Urbano-Ispizua A, Gill R, et al: Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 51:3497-3502, 1991
35. Jiang W, Kahn SM, Guillem JG, et al: Rapid detection of ras oncogenes in human tumors: Applications to colon, esophageal, and gastric cancer. Oncogene 4:923-928, 1989
36. Wallace RB, Johnson MJ, Hirose T, et al: The use of synthetic oligonucleotides as hybridization probes: II. Hybridization of oligonucleotides of mixed sequence to rabbit beta-globin DNA. Nucleic Acids Res 9:879-894, 1981
37. Conner BJ, Reyes AA, Morin C, et al: Detection of sickle cell beta S-globin allele by hybridization with synthetic oligonucleotides. Proc Natl Acad Sci U S A 80:278-282, 1983
38. Sidransky D, Von Eschenbach A, Tsai YC, et al: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706-709, 1991
39. Sidransky D, Tokino T, Hamilton SR, et al: Identification of ras oncogene mutations in the stool of patients with curab e co orecta tumors. Science 256:102-105, 1992
40. Clayton SJ, Scott FM, Walker J, et al: K-ras point mutation detection in lung cancer: Comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem 46:1929-1938, 2000
41. Beaudet AL, Belmont JW: Array-based DNA diagnostics: Let the revolution begin. Annu RevMed 59:1 13-129, 2008
42. Gundry CN, Vandersteen JG, Reed GH, et al: Amplicon melting analysis with labeled primers: A closed-tube method for differentiating homozygotes and heterozygotes. Clin Chem 49:396-406, 2003
43. Simi L, Pratesi N, Vignoli M, et al: High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colo-rectal cancer. Am J Clin Pathol 130:247-253, 2008
44. Takano T, Ohe Y, Tsuta K, et al: Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. Clin Cancer Res 13:5385-5390, 2007
45. Do H, Krypuy M, Mitchell PL, et al: High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 8:142, 2008
46. Newton CR, Graham A, Heptinstall LE, et al: Analysis of any point mutation in DNA: The amplification refractory mutation system (ARMS). Nucleic Acids Res 17:2503-2516, 1989
47. Fox JC, England J, White P, et al: The detection of K-ras mutations in colorectal cancer using the amplification-refractory mutation system. Br J Cancer 77:1267-1274, 1998
48. Whitcombe D, Theaker J, Guy SP, et al: Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol 17:804-807, 1999
49. Thelwell N, Millington S, Solinas A, et al: Mode of action and application of Scorpion primers to mutation detection. Nucleic Acids Res 28:3752-3761, 2000
50. Ahmadian A, Ehn M, Hober S: Pyrosequenc- ing: History, biochemistry and future. Clin Chim Acta 363:83-94, 2006
51. Poehlmann A, Kuester D, Meyer F, et al: K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract 203: 489-497, 2007
52. Gautschi O, Huegli B, Ziegler A, et al: Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett 254:265-273, 2007